Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Published on by Neuroscientists

Prof. Dr. Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Prof. Dr. Hongrui Meng,  Institute of Neuroscience, Soochow University, China.

Dr. Hongrui Meng is a highly accomplished neuroscientist whose academic path began with a Ph.D. in Behavioural Neuroscience from Hamamatsu University School of Medicine in Japan. He later conducted postdoctoral research in molecular neurobiology and human genetics at Juntendo University, Tokyo. Currently a professor at the Institute of Neuroscience, Soochow University, Dr. Meng leads a research team dedicated to uncovering the molecular and mitochondrial mechanisms underlying Parkinson’s disease and ALS. His work spans high-impact research projects funded by JSPS, NSFC, and other prestigious bodies. In addition to numerous scientific publications, he has contributed to diagnostic innovation through patented miRNA detection methods. His influence extends beyond academia through translational applications such as wearable technologies for Parkinson’s symptom monitoring.

Profile

Orcid

🎓 Early Academic Pursuits

Dr. Hongrui Meng began his distinguished academic journey in the field of neuroscience by earning his Ph.D. in Behavioural Neuroscience from the prestigious Hamamatsu University School of Medicine in Japan. His early education and training laid a strong foundation in experimental neuroscience, with a focus on the behavioral manifestations of neurodegenerative conditions. These formative years not only sharpened his scientific curiosity but also equipped him with the cross-disciplinary expertise to address complex neurological questions.

🧠 Professional Endeavors

Following his doctoral studies, Dr. Meng advanced his specialization through postdoctoral training in molecular neurobiology and human genetics at Juntendo University in Tokyo. There, he immersed himself in high-level research focusing on the genetic underpinnings of neurological disorders. His competence and dedication soon earned him a faculty appointment as an Assistant Professor in the Department of Research for Neurodegenerative Diseases and Dementia. His professional arc reached a significant milestone in 2020 when he was promoted to Full Professor and moved to the Institute of Neuroscience at Soochow University, where he now leads the Laboratory of Molecular Neurology.

🧬 Contributions and Research Focus

Dr. Meng’s scientific contributions center on the molecular mechanisms of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). His research bridges mitochondrial dysfunction, alpha-synuclein aggregation, and neurodegeneration. He has completed pivotal studies supported by the Japan Society for the Promotion of Science and the Takeda Pharmaceutical Foundation, delving into the role of CHCHD2 gene mutations and mitochondrial pathways. His ongoing projects funded by the National Natural Science Foundation of China (NSFC) explore mitochondrial unfolded protein responses (mtUPR), while another innovative project in Suzhou focuses on wearable technology for monitoring Parkinson’s disease symptoms—demonstrating his commitment to translational and patient-centered neuroscience.

🔬 Innovation and Scientific Output

A notable innovator, Dr. Meng has made strides in molecular diagnostic technologies. His work has led to the development of high-throughput RT-qPCR-based methods for detecting primary and precursor miRNAs, contributing to enhanced genetic analysis of neurodegenerative disorders. He holds a patent granted in South Africa and another under process in China, underscoring his role at the intersection of research and technology. Furthermore, his publications in highly regarded journals like Current Issues in Molecular Biology and Cell Communication and Signaling reflect a consistent record of impactful findings that inform both fundamental neuroscience and clinical approaches.

🏅 Accolades and Recognition

Dr. Meng’s ascent in the academic community has been marked by numerous grants, including multiple from the JSPS and NSFC, attesting to the trust placed in his research vision by top funding bodies. While a formal list of awards may be under-documented, his rapid progression from postdoctoral fellow to professor and research team leader in less than a decade speaks volumes about his recognition among peers and institutional leadership. His leadership in multi-disciplinary and international collaborations is an implicit accolade of his scientific reliability and visionary perspective.

🌍 Impact and Influence

Through his groundbreaking work on mitochondrial mechanisms and neurodegeneration, Dr. Meng is helping to reshape current understanding of Parkinson’s disease pathophysiology. His investigations into alpha-synucleinopathy and microglial disruption have provided fresh insights into cellular degeneration and neuroimmune interactions. Beyond academia, his involvement in developing wearable diagnostic tools highlights his drive to impact patient lives directly. As a consultant on neuroprotective treatments such as PD-018/19, he bridges the academic and pharmaceutical worlds to accelerate therapeutic discovery.

🔮 Legacy and Future Contributions

Looking forward, Dr. Meng is poised to be a leading figure in neurogenetic diagnostics and therapeutic innovation. His laboratory at Soochow University serves as an incubator for future discoveries in neurodegenerative disease mechanisms, and his continued work in mitochondrial research promises to inform emerging therapies. With a growing publication record, international patents, and a robust research pipeline, Dr. Meng’s legacy will be one of bridging basic neuroscience with clinical application—paving the way for novel interventions and a better understanding of brain disorders in the molecular era.

Publication

 

  • Title: Dicer Is Involved in Cytotoxicity and Motor Impairment Induced by TBPH Deficiency
    Authors: Xiang Long, Yijie Wang, Hongrui Meng
    Year: 2025

 

  • Title: Transcriptomic analysis of lipid metabolism genes in Alzheimer’s disease: highlighting pathological outcomes and compartmentalized immune status
    Authors: Sun Y., Zhang Y., Jiang M., Long X., Miao Y., Du H., Zhang T., Meng H., Ma X.
    Year: 2024

 

  • Title: CHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis
    Authors: Aya Ikeda, Hongrui Meng, Daisuke Taniguchi, Muneyo Mio, Manabu Funayama, Kenya Nishioka, Mari Yoshida, Yuanzhe Li, Hiroyo Yoshino, Tsuyoshi Inoshita et al.
    Year: 2024

 

  • Title: TDP-43 mutations-induced defects in miRNA biogenesis and cytotoxicity by differentially obstructing Dicer activity in Drosophila and in vitro
    Authors: Xiang Long, Mengni Jiang, Yongzhen Miao, Huanhuan Du, Ting Zhang, Zhuoya Ma, Jiao Li, Chunfeng Liu, Hongrui Meng
    Year: 2024

 

  • Title: A Simple Technique to Assay Locomotor Activity in Drosophila
    Authors: Long X., Du H., Jiang M., Meng H.
    Year: 2023

 

  • Title: Functional MHCI deficiency induces ADHD-like symptoms with increased dopamine D1 receptor expression
    Authors: Meng H.-R., Suenaga T., Edamura M., Nakahara D., Murakami G., Fukuda A., Ishida Y.
    Year: 2021

 

  • Title: Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a Drosophila model of Parkinson’s disease
    Authors: Imai Y., Hattori N., Inoshita T., Shiba-Fukushima K., Meng H., Hara K.Y., Sawamura N.
    Year: 2019

 

  • Title: Mutations in CHCHD2 cause α-synuclein aggregation
    Authors: Ikeda A., Nishioka K., Takanashi M., Li Y., Mori A., Okuzumi A., Izawa N., Ishikawa K.-I., Funayama M., Imai Y. et al.
    Year: 2019

 

  • Title: Parkinson’s disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling
    Authors: Mori A., Hatano T., Koinuma T., Kubo S.-I., Spratt S., Yamashita C., Okuzumi A., Imai Y., Hattori N., Inoshita T. et al.
    Year: 2019

 

  • Title: Twin CHCH proteins, CHCHD2, and CHCHD10: Key molecules of Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia
    Authors: Imai Y., Hattori N., Meng H., Shiba-Fukushima K.
    Year: 2019

 

🧾 Conclusion

Dr. Hongrui Meng’s career reflects a dynamic blend of academic excellence, molecular research innovation, and translational neuroscience. His scientific endeavors have not only enriched the understanding of neurodegenerative diseases but have also paved the way for novel diagnostic and therapeutic strategies. With a growing portfolio of impactful research, patents, and leadership in neurobiology, Dr. Meng stands out as a driving force in the global fight against neurological disorders. His work promises continued contributions to neuroscience with lasting influence on both scientific knowledge and patient care.

 

Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Dr. Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Dr.  Liliana Elena Weimer, Center For Global Health Istituto Superiore di Sanita’ Rome, Italy.

Dr. Liliana Elena Weimer is a highly accomplished physician and clinical researcher , where she has risen to the prestigious Level II “First Researcher” position. Her professional focus lies in clinical trials for infectious diseases, particularly HIV and Hepatitis C. She has played a critical role in major national and international research efforts, including collaborations with the U.S. Clinical Trials Group and leadership of the large-scale PITER cohort involving 25,000 HCV patients. She is known not only for her scientific contributions but also for her humanitarian efforts during the COVID-19 emergency. Among her recognitions is the 1st Prize at the 2019 International Congress on Hepatitis C in Seville. Throughout her career, she has exemplified scientific integrity, dedication, and service to public health.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born on December 19, 1965, in Buenos Aires to Italian parents, Dr. Liliana Elena Weimer embraced her dual heritage and committed herself to a life in medicine and research. With Italian citizenship and deep academic determination, she laid the groundwork for her career by studying medicine, ultimately finding her professional home in Italy. Her academic path, though not fully detailed, clearly led her toward a focus on clinical medicine and infectious diseases, with her earliest professional roles marking the beginning of a lifelong engagement in public health and biomedical research. Her intellectual dedication and international roots later became an asset in global research collaborations.

🩺 Professional Endeavors

Dr. Weimer’s distinguished career spans over three decades at the Italian National Institute of Health (ISS), beginning in 1985. Starting as a dedicated clinical physician, she ascended to Level III researcher status by 1990 and continued to grow into higher ranks, culminating in her success in the national Art. 15 competition for the Level II “First Researcher” role in 2022, officially backdated to 2021. Throughout her tenure at ISS, she became a central figure within the Global Health Center in Rome. Known for her tireless commitment, she often described her career not simply as a job but as a “mission,” emphasizing both her personal and professional passion for making a difference in human health.

🧪 Contributions and Research Focus

Specializing in clinical trials, Dr. Weimer has coordinated and participated in numerous groundbreaking studies in HIV and Hepatitis C (HCV). Since the early 1990s, she has collaborated closely with renowned figures such as Prof. Giovanni Rossi, Prof. Stefano Vella, and Prof. Gianni Rezza, contributing to some of the most pivotal HIV antiretroviral therapy trials in history. Her research efforts extended to co-leading and organizing both national and international multicenter clinical trials. Notably, she has been at the forefront of the PITER study, a major nationwide cohort that follows 25,000 patients undergoing HCV treatment—one of the most comprehensive initiatives in Italy in the fight against hepatitis.

🌍 Global Collaborations and Humanitarian Engagement

Her impact extends beyond Italy, thanks to her active involvement with the U.S.-based American Clinical Trials Group on HIV studies. These collaborations have enhanced international understanding and treatment of HIV/AIDS. In addition to her clinical and research commitments, Dr. Weimer also devoted herself to frontline service during the COVID-19 pandemic. Volunteering both with the Civil Protection unit and at Bambino Gesù Children’s Hospital, she demonstrated profound humanitarian values. Her presence during a critical time underscored her belief in serving communities not just from behind a lab desk but also on the ground, directly supporting patients and health systems under strain.

🏅 Accolades and Recognition

Dr. Weimer’s work has been acknowledged at both national and international levels. One of the most prominent recognitions she received was the 1st Prize at the International Congress on Hepatitis C held in Seville in November 2019, a testament to her excellence and influence in the field of infectious disease research. Her achievements are not only measured in accolades but also in the tangible difference her work has made in advancing therapy options and clinical management of chronic viral diseases. Her rise within the ISS and the trust placed in her leadership of major research projects further affirm her standing within the scientific community.

💡 Impact and Influence

Over the course of her extensive career, Dr. Weimer has significantly shaped clinical research strategies in Italy, especially regarding chronic viral infections. Her coordination of thousands of patient cases within structured clinical trials has informed policy decisions and improved treatment protocols nationwide. Her presence at the ISS has also influenced future generations of researchers and clinicians, many of whom benefited from her mentorship, leadership, and example of scientific integrity. Through her rigorous methods and patient-focused approach, she has played a key role in Italy’s standing as a leader in global health research, especially in relation to HIV and HCV.

🔬 Legacy and Future Contributions

Looking forward, Dr. Weimer’s contributions will continue to echo through the fields of virology and clinical medicine. Her involvement in the PITER cohort and other studies has laid down essential groundwork for long-term epidemiological surveillance and patient care strategies. With her appointment as First Researcher, she enters a new chapter of leadership, likely to drive more innovative, patient-centered research initiatives in global health. Her legacy lies not only in her publications or awards but also in the thousands of lives improved by the treatments she helped to test, refine, and implement. The combination of scientific rigor and heartfelt service defines her enduring contribution to modern medicine.

Publication

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C – TR Morgan, MG Ghany, HY Kim, KK Snow, ML Shiffman, JL De Santo, … – 2010

 

  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients – SL George, BR Bacon, EM Brunt, KL Mihindukulasuriya, J Hoffmann, … – 2009

 

  • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis – V Saxena, L Nyberg, M Pauly, A Dasgupta, A Nyberg, B Piasecki, … – 2015

 

  • Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy – D Persaud, SC Ray, J Kajdas, A Ahonkhai, GK Siberry, K Ferguson, … – 2007

 

  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study – EB Tapper, BR Bacon, MP Curry, DT Dieterich, SL Flamm, LE Guest, … – 2016

 

  • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with< 50 copies/ml HIV-1 RNA – S Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, LE Weimer, … – 2009

 

  • Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study – R Mellado-Artigas, LE Mujica, ML Ruiz, BL Ferreyro, F Angriman, E Arruti, … – 2021

 

  • A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients – M Floridia, R Bucciardini, D Ricciardulli, V Fragola, MF Pirillo, LE Weimer, … – 1999

 

  • Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort – LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, … – 2017

 

  • Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER network – LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, … – 2017

 

🏁 Conclusion

Dr. Weimer stands as a distinguished figure in the field of global health research, with deep expertise in clinical trials and infectious diseases. Her legacy is marked by landmark contributions to HIV and HCV treatment protocols, influential collaborations, and compassionate public service. Her ongoing work continues to shape public health policy and medical research in Italy and beyond. As she advances in her leadership role at the ISS, her experience, insight, and dedication will remain vital to future innovations in clinical research and global health.